Novel Use of Intravenous Immunoglobulin G in Complement Factor H Missense Mutation: A Case Report

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Progress in transplantation

• Publication date

  2013-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.7182/pit2013151PMID 23996939
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thrombotic microangiopathy, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Rare manifestations of Russell’s viper (Daboia russelii) envenoming in Sri Lanka

  2021cited by this paper
• Eculizumab in a patient with dense-deposit disease.

  2012cited by this paper
• Eculizumab for dense deposit disease and C3 glomerulonephritis.

  2012cited by this paper
• Successful simultaneous liver-kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor H.

  2011cited by this paper
• Protection of Nonself Surfaces from Complement Attack by Factor H-Binding Peptides: Implications for Therapeutic Medicine

  2011cited by this paper
• Production of biologically active complement factor H in therapeutically useful quantities.

  2011cited by this paper
• Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome.

  2011cited by this paper
• Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.

  2010cited by this paper
• Atypical hemolytic uremic syndrome

  2010cited by this paper
• Transplantation in Atypical Hemolytic Uremic Syndrome

  2010cited by this paper
• Renal disease associated with inherited disorders of the complement system

  2009cited by this paper
• Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.

  2009cited by this paper
• Liver-kidney transplantation to cure atypical hemolytic uremic syndrome.

  2009cited by this paper
• Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation.

  2006cited by this paper
• Favorable Long‐Term Outcome after Liver‐Kidney Transplant for Recurrent Hemolytic Uremic Syndrome Associated with a Factor H Mutation

  2006cited by this paper
• F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins

  2003cited by this paper
• IVIG – mechanisms of action

  2003cited by this paper
• Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

  2001cited by this paper
• Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

  2001cited by this paper
• High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes.

  1996cited by this paper

• Liver–kidney transplantation to cure atypical HUS: still an option post-eculizumab?

  2014cites this paper